Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2017

View Archived Issues

Fate Therapeutics describes novel immune cell modulation compositions

Beijing Marino Biotechnology presents new CAR-T cells expressing non-functional EGFR

Memantine improves Glasgow Coma Scale scores in patients with traumatic brain injury

Novel mouse model of Arid1b haploinsufficiency with neuropsychiatric phenotypes

Krebs cycle explored for new susceptibility genes in pheochromocytomas and paragangliomas

Rho-associated kinase identified as a treatment target in neuroblastoma

Vectura Group enters global development agreement with Dynavax for smart nebuliser technology

FDA grants orphan drug status to Curtana Pharmaceutical's CT-179

Cancer Research UK and Newcastle University extend collaboration with Astex Pharmaceuticals

Exelixis submits sNDA to the FDA for Cabometyx

FDA accepts Seattle Genetics' supplemental BLA based on data from the phase III ALCANZA trial

Spotlight Innovation enters into sponsored research agreement to develop new therapies for SMA

Shire's lifitegrast marketing authorization application validated in Europe

Moleculin Biotech acquires WP-1122 drug substance to advance testing

Photocure files sNDA with FDA for blue light cystoscopy with Cysview

Pluristem starts pilot study to test PLX-R18 cell therapy for acute radiation syndrome

Metacrine and Novo Nordisk enter collaboration to develop fibroblast growth factor 1 variants

Abeona Therapeutics expands gene therapy trial for individuals with mucopolysaccharidosis type IIIA

Novo Nordisk presents SUSTAIN 7 trial results for semaglutide in type 2 diabetes

Conatus completes enrollment in ENCORE-NF trial of emricasan

First cohort completes LTX-315 monotherapy in metastatic solid tumors trial

SillaJen and NCI to collaborate on the development of combination therapy with Pexa-Vec

Lexicon reports additional positive data from pivotal phase III sotagliflozin trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...